<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>Adenosine 6-12-12 Approach</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Bryan Hayes, PharmD</div><div><strong>Updated:</strong> <!-- -->12/6/2012</div></div><div class="card__content"><h1 id="adenosine-6-12-12-adenosine-approach">Adenosine: 6-12-12 adenosine approach</h1>
<p>The ACLS-recommended dosing strategy of 6 mg, 12 mg, and 12 mg for <span class="drug">adenosine</span> may not be appropriate in every situation. There are a few instances when lower or higher dosing should be considered.</p>
<p><em>Caveat:</em> All recommendations are data-based, but many factors affect successful conversion of paroxysmal supraventricular tachycardia (PSVT) including proper line placement and administration technique.</p>
<h2 id="option-1-starting-at-higher-dose">Option 1: Starting at higher dose</h2>
<p><strong>Caffeine and theophylline:</strong> Caffeine is an <span class="drug">adenosine</span> blocker and can interfere with the successful reversion of PSVT. In fact, ingestion of caffeine less than 4 hours before a 6-mg <span class="drug">adenosine</span> bolus significantly reduced its effectiveness in the treatment of PSVT. An increased initial <span class="drug">adenosine</span> dose may be indicated for these patients.</p>
<p>Remember that theophylline may require higher dosing as well, because it is similar to caffeine (another methylxanthine), but is not prescribed much in the U.S. anymore.</p>
<p><strong><em>Recommended dosing strategy</em></strong> [<a href="http://www.ncbi.nlm.nih.gov/pubmed/20003123">Cabalag, 2009</a>]:</p>
<ul>
<li>1st dose: 12 mg (instead of 6)</li>
<li>2nd/3rd doses: 18 mg (instead of 12)</li>
</ul>
<h2 id="option-2-starting-at-lower-dose">Option 2: Starting at lower dose</h2>
<p><strong>Central Line:</strong> The initial <span class="drug">adenosine</span> dose should be reduced if administered through a central line. Remember a central line delivers the <span class="drug">adenosine</span> right where you need it. This recommendation is supported by the 2010 ACLS guidelines. Cases of prolonged bradycardia and severe side effects have been reported after full-dose <span class="drug">adenosine</span> through a central line.</p>
<p><strong>Carbamazepine or Dipyridamole:</strong> Lower dose for patients on <span class="drug">carbamazepine</span> or <span class="drug">dipyridamole</span> </p>
<p><strong>Transplanted heart:</strong> Lowr dose for patients with heart transplants</p>
<p><strong><em>Recommended dosing strategy</em></strong>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11858927">Chang, 2002</a>; <a href="http://www.ncbi.nlm.nih.gov/pubmed/20956256">Neumar, 2010</a>; <a href="http://www.ncbi.nlm.nih.gov/pubmed/8354807">Mc-Intosh-Yellin, 1993</a>]:</p>
<ul>
<li>1st dose: 3 mg (instead of 6)</li>
<li>2nd/3rd doses: 6 mg (instead of 12)</li>
</ul>
<p><strong><a href="https://www.aliem.com/2012/is-6-12-12-adenosine-approach-always/">ALiEM Blog Post</a></strong></p>
<h2 id="references">References</h2>
<ul>
<li>McIntosh-Yellin NL, et al. Safety and efficacy of central intravenous bolus administration for termination of supraventricular tachycardia. J Am Coll Cardiol 1993;22:741-5. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/8354807">PubMed</a>]</li>
<li>Cabalag MS, et al. Recent caffeine ingestion reduces adenosine efficacy in the treatment of paroxysmal supraventricular tachycardia. Acad Emerg Med 2009;17(1):44-9. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/20003123">PubMed</a>]</li>
<li>Chang M, et al. Adenosine dose should be less when administered through a central line. J Emerg Med 2002;22(2):195-8 [<a href="http://www.ncbi.nlm.nih.gov/pubmed/11858927">PubMed</a>]</li>
<li>Neumar RW, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122:S729-S767. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/20956256">PubMed</a>]</li>
</ul>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"adenosine","title":"Adenosine 6-12-12 Approach","authors":["Bryan Hayes, PharmD"],"categories":[{"slug":"cardiovascular","name":"Cardiovascular"},{"slug":"pharmacology","name":"Pharmacology"},{"slug":"critical-care","name":"Critical Care"}],"created":"2012/12/06","updated":null,"body":"\n# Adenosine: 6-12-12 adenosine approach\n\nThe ACLS-recommended dosing strategy of 6 mg, 12 mg, and 12 mg for \u003cspan class=\"drug\"\u003eadenosine\u003c/span\u003e may not be appropriate in every situation. There are a few instances when lower or higher dosing should be considered.\n\n_Caveat:_ All recommendations are data-based, but many factors affect successful conversion of paroxysmal supraventricular tachycardia (PSVT) including proper line placement and administration technique.\n\n## Option 1: Starting at higher dose\n\n**Caffeine and theophylline:** Caffeine is an \u003cspan class=\"drug\"\u003eadenosine\u003c/span\u003e blocker and can interfere with the successful reversion of PSVT. In fact, ingestion of caffeine less than 4 hours before a 6-mg \u003cspan class=\"drug\"\u003eadenosine\u003c/span\u003e bolus significantly reduced its effectiveness in the treatment of PSVT. An increased initial \u003cspan class=\"drug\"\u003eadenosine\u003c/span\u003e dose may be indicated for these patients.\n\nRemember that theophylline may require higher dosing as well, because it is similar to caffeine (another methylxanthine), but is not prescribed much in the U.S. anymore.\n\n**_Recommended dosing strategy_** \\[[Cabalag, 2009](http://www.ncbi.nlm.nih.gov/pubmed/20003123)]:\n\n- 1st dose: 12 mg (instead of 6)\n- 2nd/3rd doses: 18 mg (instead of 12)\n\n## Option 2: Starting at lower dose\n\n**Central Line:** The initial \u003cspan class=\"drug\"\u003eadenosine\u003c/span\u003e dose should be reduced if administered through a central line. Remember a central line delivers the \u003cspan class=\"drug\"\u003eadenosine\u003c/span\u003e right where you need it. This recommendation is supported by the 2010 ACLS guidelines. Cases of prolonged bradycardia and severe side effects have been reported after full-dose \u003cspan class=\"drug\"\u003eadenosine\u003c/span\u003e through a central line.\n\n**Carbamazepine or Dipyridamole:** Lower dose for patients on \u003cspan class=\"drug\"\u003ecarbamazepine\u003c/span\u003e or \u003cspan class=\"drug\"\u003edipyridamole\u003c/span\u003e \n\n**Transplanted heart:** Lowr dose for patients with heart transplants\n\n**_Recommended dosing strategy_**\\[[Chang, 2002](http://www.ncbi.nlm.nih.gov/pubmed/11858927); [Neumar, 2010](http://www.ncbi.nlm.nih.gov/pubmed/20956256); [Mc-Intosh-Yellin, 1993](http://www.ncbi.nlm.nih.gov/pubmed/8354807)]:\n\n- 1st dose: 3 mg (instead of 6)\n- 2nd/3rd doses: 6 mg (instead of 12)\n\n**[ALiEM Blog Post](https://www.aliem.com/2012/is-6-12-12-adenosine-approach-always/)**\n\n## References\n\n- McIntosh-Yellin NL, et al. Safety and efficacy of central intravenous bolus administration for termination of supraventricular tachycardia. J Am Coll Cardiol 1993;22:741-5. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8354807)]\n- Cabalag MS, et al. Recent caffeine ingestion reduces adenosine efficacy in the treatment of paroxysmal supraventricular tachycardia. Acad Emerg Med 2009;17(1):44-9. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20003123)]\n- Chang M, et al. Adenosine dose should be less when administered through a central line. J Emerg Med 2002;22(2):195-8 [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11858927)]\n- Neumar RW, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122:S729-S767. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20956256)]\n"}}},"page":"/card","pathname":"/card","query":{"slug":"adenosine"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>